Oma Savings Bank Plc's Annual Report and Financial Statements 2022 published
OMA SAVINGS BANK PLC, STOCK EXCHANGE RELEASE 9 MARCH 2023 AT 10.00 A.M. EET, ANNUAL FINANCIAL REPORT
Oma Savings Bank Plc's Annual Report and Financial Statements 2022 published
Oma Savings Bank Plc’s (OmaSp or Company) Annual Report 2022 has been published in Finnish and English on website www.omasp.fi/investors today. The Annual Report 2022 includes the Report by the Board of Directors, the Group’s and Parent Company’s Financial Statements as well as the Sustainability Report.
The Company has also published the Corporate Governance Statement, the Capital and Risk Management Report and the Remuneration Report in Finnish and English.
OmaSp also publishes the Finnish version of the Report by the Board of Directors and Financial Statements in accordance with the European Single Electronic Format (ESEF) reporting requirements as an XHTML file. The primary statements in the consolidated financial statements have been labelled with XBRL tags. Authorised Public Accountants KPMG Oy Ab has assured the XHTML file and the XBRL tags included in it. The ESEF file can be found as an attachment to this release and on webpage https://sijoittaminen.omasp.fi/en/annual-reports
The above-mentioned documents are available as attachments to this release and on the company's website. The reports are available in digital versions.
Oma Savings Bank Plc
Minna Sillanpää, CCO, puh. +358 50 66592, firstname.lastname@example.org
Nasdaq Helsinki Ltd
OmaSp is a growing Finnish bank and the largest savings bank in Finland based on total assets. About 450 professionals provide nationwide services through OmaSp’s 45 branch offices and digital service channels to over 200,000 private and corporate customers. OmaSp focuses primarily on retail banking operations and provides its clients with a broad range of banking services both through its own balance sheet as well as by acting as an intermediary for its partners’ products. The intermediated products include credit, investment and loan insurance products. OmaSp is also engaged in mortgage banking operations.
OmaSp core idea is to provide personal service and to be local and close to its customers, both in digital and traditional channels. OmaSp strives to offer premium level customer experience through personal service and easy accessibility. In addition, the development of the operations and services is customer-oriented. The personnel is committed and OmaSp seeks to support their career development with versatile tasks and con-tinuous development. A substantial part of the personnel also own shares in OmaSp.
- OmaSp Annual Report 2022
- OmaSp Capital and Risk Management Report 2022
- OmaSp Remuneration Report 2022
- OmaSp Corporate Governance Statement 2022
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
TRESU Investment Holding A/S – Registration for investor call28.3.2023 11:04:29 CEST | Press release
TRESU INVESTMENT HOLDING A/S ANNOUNCEMENT NO. 02.2023 28.03.2022 TRESU Investment Holding A/S is pleased to invite you to the financial results call, which is being held: Wednesday, 5 April 2022, at 11am CET. The Annual Report will be presented by Christian Jacob Flarup, CEO and Torben Børsting, CFO. After the presentation there will be an opportunity for Q+A. A recording of the results call will be made available for four hours on the TRESU IR website. To register for the investor call, please send an e-mail to Financial manager at TRESU A/S Finn Holm no later than 4 April 2023 9am CET - email@example.com Christian Jacob Flarup CEO, TRESU For further details, please contact: CEO, Christian Jacob Flarup, phone: +45 2027 7971 CFO, Torben Børsting, phone: +45 5130 2780 Attachment Quarterly reporting - Call - 2022 Q4
Alvotech Provides Update on Corporate Sustainability Framework28.3.2023 11:00:00 CEST | Press release
Alvotech (Nasdaq: ALVO) (the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced an update to the Company’s Corporate Sustainability framework, including the release of key environmental, social and governance (“ESG”) indicators for 2022. “As part of our commitment to improve the sustainability of healthcare by providing access to more affordable biologic medicines, we recognize that corporate sustainability is closely linked to our long-term success and the value we may bring to patients, healthcare providers and all of our stakeholders,” said Robert Wessman, Founder, Chairman and CEO of Alvotech. Data on key ESG indicators for 2020-2022 can be found on Alvotech’s dedicated web portal. Alvotech’s Board of Directors has established a Corporate Sustainability Committee (CSC) to oversee the Company’s strategy as it relates to ESG matters. Alvotech’s corporate headquarters, purpose-built manuf
Zealand Pharma Announces Positive Phase 1 Clinical Results with Amylin Analogue ZP839628.3.2023 10:54:21 CEST | Press release
Company announcement – No. 7 / 2023 Zealand Pharma Announces Positive Phase 1 Clinical Results with Amylin Analogue ZP8396 Dose-dependent body weight reductions of up to a mean of 4.2% from baseline (4.8% placebo corrected) following a single dose of ZP8396In development as a non-incretin peptide therapyfor the potential management of overweight and obesity Copenhagen, Denmark, March 28, 2023 – Zealand Pharma A/S (Nasdaq: ZEAL) (“Zealand”) (CVR-no. 20045078) a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced Phase 1a results for ZP8396, the company’s amylin analogue. The first-in-human study was designed to assess safety, pharmacokinetic (PK) and pharmacodynamic effects of ZP8396 in healthy lean and overweight people. “We are excited by the potential of amylin as an alternative, non-incretin treatment for overweight and obesity, and are very encouraged that treatment with a single dose of ZP8396 led to meaningful dose
Indkaldelse til ordinær generalforsamling i SKAKO A/S28.3.2023 10:50:52 CEST | pressemeddelelse
Til NASDAQ OMX Copenhagen A/S GlobeNewswire Faaborg, den 28. marts 2023 Selskabsmeddelelse nr. 5/2023 Indkaldelse til ordinær generalforsamling i SKAKO A/S SKAKO A/S indkalder til ordinær generalforsamling i selskabet til afholdelse onsdag den 19. april 2023, kl. 15.00 på selskabets adresse. Indkaldelsen er sket jf. selskabets vedtægter § 7 og er tilgængelig på selskabets hjemmeside. Udbytte På baggrund af det stærke resultat i 2022 og kapitalstrukturen i SKAKO A/S pr. 31. december 2022 anbefaler bestyrelsen en udbytteudlodning på DKK 5 pr. aktie svarende til 61,0% af årets resultat og en samlet udbytteudlodning på DKK 15,4 mio. Med en aktiekurs på 62,6 kr. pr. 31. december 2022 svarer det til en udbytteprocent på 8,0%. Udbyttebetalingen vil være et behandlingspunkt på agendaen for den ordinære generalforsamling 19. april 2023. Ex-udbytte dato: 19. april 2023 Optagelsesdato: 20. april 2023 Udbetalingsdato: 24. april 2023 Med venlig hilsen SKAKO A/S Jens Wittrup Willumsen Bestyrelsesfor
Aalborg Boldspilklub A/S indkalder til ordinær generalforsamling28.3.2023 10:50:49 CEST | pressemeddelelse
NASDAQ Copenhagen A/S Børsmeddelelse nr. 2023/06 Aalborg, 28. marts 2023 Vedhæftet indkaldelse og dagsorden til ordinær generalforsamling i Aalborg Boldspilklub A/S onsdag 19. april 2023 kl. 16.00 på Aalborg Portland Park. Venlig hilsen Aalborg Boldspilklub A/S Thomas Bælum Administrerende direktør For yderligere oplysninger: Thomas Bælum 2251 7901 Vedhæftede filer Dagsorden 2023 - Inkl Bilag A og Bilag BAAB_ Brevstemme blanket_GF2023_v5